Search PubMed⌕ Search

Biomedical subjects

R Eberl

Publications and source records attributed to R Eberl.

At least 73 records · Page 4Linked to original sources
PubMed1976

[Extra-articular manifestations of chronic polyarthritis].

Although the chronic destructive joint processes dominate the clinical picture of chronic rheumatoid arthritis, it must not been forgotten that the disease is a systemic one, whereby certain organs or organ systems are affected either clinically or subclinically. The various possible pathogenetic mechanisms are discussed and the particular type of patient with rheumatoid arthritis who appears to be prone to extra-articular manifestations is described. Subsequently, the individual organic manifestations and the clinical picture are discussed, as well as the incidence and significance of these features.

Amyloidosis↗
PubMed1976

[The effect of oxyphenbutazone and flufenamic acid in vitro on the purine salvage pathway of human lymphocytes (author's transl)].

The effect of oxyphenbutazone and flufenamic acid was investigated on the enzymes of the purine salvage pathway of human lymphocytes in vitro. A distinct decrease in adenine-phosphoribosyltransferase activity and in guanine-hypoxanthine-phosphoribosyltransferase activity was observed following the administration of either pharmacological preparation. The loss of enzyme activity was 23 to 39%. The pharmaceuticals were used at a concentration of 50 mug%.

Adenine Phosphoribosyltransferase↗
PubMed1976

Prolonged treatment with azapropazone.

In an open study of 40 patients with chronic rheumatoid polyarthritis, azapropazone was given alone in daily doses between 1200 mg. and 1800 mg. over a period of 6 months. Six patients were withdrawn, 2 because of side-effects (1 with an allergic-type rash; 1 with ankle oedema) and 4 because azapropazone alone did not provide adequate control of their pain and discomfort. Objective assessments showed that 18 patients had a 'good' or 'very good' response to treatment, and a further 16 showed moderate improvement. These findings were supported by the patients' subjective assessment of the change in their condition from the start of the trial. In addition, 22 patients showed a significant decrease in erythrocyte sedimentation rate. There was no evidence of adverse effects on any of the haematological and biochemical parameters measured, and the incidence of side-effects was low.

Adult↗
PubMed1976

Comparative clinical trial with a new substance, Diftalone, versus indomethacin in 30 patients affected with rheumatoid arthritis.

During a double-blind, randomized study on 30 patients affected with classic or definite rheumatoid arthritis, the efficacy and safety of treatment with diftalone in a per oral dosage of 500 mg/day were compared with those of indomethacin given orally at doses of 50-75 mg/day initially and 100 mg/day subsequently, for a treatment period of 24 months. In this long-term study, diftalone demonstrated that its effectiveness and safety in the treatment of rheumatoid arthritis are clearly comparable to those of indomethacin.

Administration, Oral↗
PubMed1976

[Sulindac: Clinical test of a new antiinflammatory agent in rheumatoid arthritis (author's transl)].

Sulindac, a new non steroidal antiinflammatory agent has been compared with acetylsalicylic-acid in a six week controlled double blind study in 28 patients with rheumatoid arthritis. In continuation of this study all patients have been treated with Sulindac up to 18 months. Sulindac has proved to be statistically significant superior to acetylsalicylic-acid as regarding the achieve of pain during the day, of morning stiffness, of gripping of the right hand and evaluation of patients response to the drug. Moreover markedly fewer adverse reactions especially of the gastrointestinal tract were seen. During the following long term study, when 19 patients were treated with Sulindac, a further statistically significant improvement of all controlled parameters up to the complete relief of complaints was observed. A reduction of the daily dose could be established. Laboratory evaluations as well as controlls of EKG and blood pressure showed no evidence of any organ toxicity of this drug.

Adult↗
PubMed1975

[Generalized secondary amyloidosis in patients with chronic rheumatoid arthritis (author's transl)].

During a period of 6 years (1968 to 1973) 177 patients with rheumatoid arthritis were submitted on one or more occasions to biopsy of the rectal mucosa for the diagnosis of amyloidosis. The indications for biopsy were as follows: 1. proteinuria, even in an intermittent form, 2. progressive type of rheumatoid arthritis with high inflammatory activity, 3. rheumatoid arthritis of longer than 2 years duration with a marked tendency to joint destruction. The histological specimens were stained with Congo red and investigated in polarized light. The biopsy for amyloidosis was positive in 80 patients (45.2%) of whom 14 showed no proteinuria, even of an intermittent nature. Patients with rheumatoid arthritis survived maximally 5 years after amyloidosis had been diagnosed. No successful therapy of amyloidosis has been devised.

Adult↗
PubMed1975

[In vitro investigations on the influence of various antirheumatic drugs on the enzymes of the purine salvage pathway (author's transl)].

On testing the effect of 5 drugs (azapropazone, flufenamic acid, indomethacin, oxyphenbutazone and prednisolone) commonly used in the therapy of rheumatic diseases on 3 enzymes of the purine salvage pathway (adenine-phosphoribosyltransferase, guanine-phosphoribosyltransferase and hypoxanthine-phosphoribosyltransferase) a distinct inhibitory effect of oxyphenbutazone and flufenamic acid was noted. A particularly marked effect was observed on adenine-phosphoribosyltransferase at the applied concentration (50 mug%) by both drugs but also guanine-phosphoribosyltransferase and hypoxanthine-phosphoribosyltransferase indicated reduced activities.

Adenine Phosphoribosyltransferase↗
PubMed1975

[Complications in chrysotherapy in 268 patients].

Side effects of chrysotherapy in 268 patients with rheumatoid arthritis, are reported. The incidence of side effects of all drugs used (Sodiumaurothiosulfate, Aurothiopolypeptide, Sodiumaurothiomalate) was approximately equal. The most common side effects were eosinophilia, exanthema, itching, albuminemia and leukopenia.

Arthritis↗